Minerva Neurosciences, Inc. (NERV) EPS Estimated At $-0.37

October 16, 2018 - By Adrian Mccoy

Minerva Neurosciences, Inc. (NASDAQ:NERV) Logo

Analysts expect Minerva Neurosciences, Inc. (NASDAQ:NERV) to report $-0.37 EPS on November, 5.They anticipate $0.09 EPS change or 32.14 % from last quarter’s $-0.28 EPS. After having $-0.32 EPS previously, Minerva Neurosciences, Inc.’s analysts see 15.63 % EPS growth. The stock increased 7.88% or $0.78 during the last trading session, reaching $10.68. About 158,665 shares traded. Minerva Neurosciences, Inc. (NASDAQ:NERV) has risen 41.89% since October 17, 2017 and is uptrending. It has outperformed by 26.27% the S&P500.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company has market cap of $414.11 million. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It currently has negative earnings. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder.

More notable recent Minerva Neurosciences, Inc. (NASDAQ:NERV) news were published by: Seekingalpha.com which released: “The Verdict On Minerva” on October 09, 2018, also Seekingalpha.com with their article: “Minerva continues rally, up 9%” published on September 20, 2018, Nasdaq.com published: “Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals …” on October 16, 2018. More interesting news about Minerva Neurosciences, Inc. (NASDAQ:NERV) were released by: Uk.Finance.Yahoo.com and their article: “Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying” published on October 10, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping …” with publication date: September 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: